ProKidney CEO to present at J.P. Morgan Healthcare Conference on cell therapy for chronic kidney disease.
Quiver AI Summary
ProKidney Corp., a clinical-stage cell therapy company focused on chronic kidney disease (CKD), has announced that its CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The management team will also conduct one-on-one meetings during the event. The presentation will be available via live webcast, with a replay accessible for 30 days afterward. ProKidney's lead product candidate, rilparencel (REACT®), is an innovative autologous cell therapy currently in Phase 3 trials aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes. Further information can be found on their website.
Potential Positives
- ProKidney's CEO will present at the prestigious J.P. Morgan Healthcare Conference, enhancing company visibility and credibility in the healthcare industry.
- The company is actively engaging with investors through one-on-one meetings, indicating a proactive approach to stakeholder communication.
- ProKidney's lead product candidate, rilparencel, is in a Phase 3 clinical trial, demonstrating ongoing commitment to advancing innovative treatments for chronic kidney disease.
- The presentation and ongoing clinical study underscore ProKidney's position as a pioneer in cell therapy for chronic kidney disease, potentially attracting interest from investors and partners.
Potential Negatives
- There is no mention of any recent data or results from ongoing studies, which could raise concerns about the progress or effectiveness of their lead product candidate, rilparencel.
- As a late clinical-stage company, there may be pressure for ProKidney to share more substantial progress on their upcoming clinical trials, leading to potential scrutiny if expectations are not met.
- The timing of the presentation and ongoing Phase 3 study could indicate a critical juncture for the company that may result in visibility issues if the product does not meet market expectations before or after the conference.
FAQ
What is ProKidney Corp. focused on?
ProKidney Corp. specializes in cell therapy for chronic kidney disease (CKD).
When is ProKidney’s presentation at the J.P. Morgan Healthcare Conference?
The presentation is scheduled for Wednesday, January 14, 2026, at 8:15 AM PST.
How can I access the live webcast of the presentation?
The live webcast can be found in the “Events” section of ProKidney’s Investor Relations webpage.
What is ProKidney’s lead product candidate?
ProKidney’s lead product candidate is rilparencel, a patented autologous cell therapy.
Where can I find more information about ProKidney?
More information is available on ProKidney’s website at www.prokidney.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PROK Insider Trading Activity
$PROK insiders have traded $PROK stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $PROK stock by insiders over the last 6 months:
- BRIAN JG PEREIRA has made 0 purchases and 4 sales selling 757,162 shares for an estimated $1,884,577.
- DARIN J. WEBER (Chief Regulatory Officer) sold 103,480 shares for an estimated $312,509
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PROK Hedge Fund Activity
We have seen 51 institutional investors add shares of $PROK stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUVRETTA CAPITAL MANAGEMENT, LLC added 12,341,266 shares (+inf%) to their portfolio in Q3 2025, for an estimated $29,865,863
- MORGAN STANLEY added 6,747,022 shares (+inf%) to their portfolio in Q3 2025, for an estimated $16,327,793
- BLEICHROEDER LP added 2,000,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,840,000
- MILLENNIUM MANAGEMENT LLC added 1,956,378 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,734,434
- VANGUARD GROUP INC added 1,564,116 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,785,160
- BLACKROCK, INC. added 1,277,203 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,090,831
- GEODE CAPITAL MANAGEMENT, LLC added 1,096,782 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,654,212
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PROK Analyst Ratings
Wall Street analysts have issued reports on $PROK in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/16/2025
- UBS issued a "Buy" rating on 07/15/2025
To track analyst ratings and price targets for $PROK, check out Quiver Quantitative's $PROK forecast page.
$PROK Price Targets
Multiple analysts have issued price targets for $PROK recently. We have seen 3 analysts offer price targets for $PROK in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $12.0 on 12/16/2025
- Eliana Merle from UBS set a target price of $8.0 on 07/15/2025
- Vamil Divan from Guggenheim set a target price of $7.0 on 07/14/2025
Full Release
WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 44 th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.
44
th
Annual J.P. Morgan Healthcare Conference
Date:
Wednesday, January 14, 2026
Time:
8:15am PST
Format:
Presentation
Webcast:
Link
The live webcast will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com . Following the completion of the event, a replay will be available for 30 days.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT
®
), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit
www.prokidney.com
.
ProKidney Contact
Ethan Holdaway
[email protected]
Media Contact
Audra Friis
[email protected]
Investor Relations Contact
Daniel Ferry
[email protected]
